Dahan succeeds Saad as Alkeus CEO
Plus: Fox becomes interim CEO of Alphina and updates from Inovio and BenevolentAI
Michel Dahan will take over from Leonide Saad as president and CEO of Alkeus Pharmaceuticals Inc. Dahan was SVP and COO of Akebia Therapeutics Inc. (NASDAQ:AKBA) and joined Alkeus’ board in January 2023. Saad, who co-founded the company, will become CSO. Alkeus added that Executive Chairman Joshua Boger had become chairman. Alkeus is developing gildeuretinol acetate to treat Stargardt disease and geographic atrophy.
Serial entrepreneur Barbara Fox became interim CEO of Alphina Therapeutics Inc., a New Haven, Conn.-based start-up. The company hasn't revealed any information about its goals or pipeline, but has said its founders have expertise in DNA repair, metabolism and synthetic lethality. Fox was CEO of Rheos Medicines Inc., which was backed by Third Rock Ventures. Before that, she was CEO of Tilos Therapeutics Inc., acquired by Merck & Co. Inc. (NYSE:MRK) in 2019 for up to $773 million, and of Avaxia Biologics Inc. in 2005-15. Alphina’s website said Mark Cockett had served as president and CEO since 2022...